STOCK TITAN

Accuray Incorp Stock Price, News & Analysis

ARAY NASDAQ

Company Description

Company Overview

Accuray Incorp (NASDAQ: ARAY) is a pioneering radiation oncology company dedicated to developing, manufacturing, and supporting innovative treatment solutions. With its robust portfolio of advanced radiotherapy systems, Accuray stands out in the field of robotic radiosurgery and precision radiation treatment. Technologies such as CyberKnife and Radixact integrate real-time tracking, advanced imaging, and dynamic treatment planning to deliver sub-millimetre accuracy when treating tumors. This unique blend of robotics and radiation therapy is essential for accurate, effective, and efficient cancer treatment.

Core Technologies and Capabilities

Accuray’s solutions are designed to meet the complex needs of modern oncology. The company’s systems automatically track and adjust to patient and tumor motion, ensuring delivery of high doses of radiation with exceptional precision. Key technologies include:

  • Real-Time Motion Tracking: Automated tracking systems that detect and correct patient movements during treatment.
  • Advanced Imaging Integration: Solutions like ClearRT provide diagnostic-quality imaging to guide therapy, ensuring optimal patient positioning and treatment accuracy.
  • Adaptive Treatment Planning: Innovative planning systems such as the Accuray Precision TPS allow clinicians to adapt treatment plans in real-time, accounting for changes in tumor characteristics and patient anatomy.
  • Robotic Radiosurgery: The CyberKnife System is a testament to the integration of robotics with medical imaging, delivering ultra-hypofractionated treatments in just a few outpatient sessions.

Market Position and Business Model

Accuray operates in a competitive global market characterized by rapid technological advances and high clinical demands. The company’s business model is built around the development and commercialization of cutting-edge devices that support a complete continuum of care—from pre-treatment planning to post-treatment care. By partnering with hospitals, cancer centers, and clinicians, Accuray not only provides state-of-the-art equipment but also offers training and support services, enhancing operational efficiencies in radiation oncology departments.

Innovation and Industry Influence

Innovation is at the heart of Accuray’s operations. The constantly evolving product portfolio, which includes enhancements in imaging, treatment planning, and adaptive delivery technologies, has positioned the company as a critical player in improving patient access to high-precision radiotherapy. These innovations have garnered recognition across global markets, particularly in regions with growing demand for advanced cancer care solutions.

Clinical Impact and Patient Care

The primary goal of Accuray’s technologies is to help patients live longer and better lives by offering treatments that are both effective and minimally disruptive. The advanced radiation therapy systems are designed to reduce treatment times, lower the risk of side effects, and deliver high-quality, personalized care. Clinicians benefit from enhanced workflow efficiencies and the ability to treat a diverse range of cancers—from common malignancies to complex cases that require sophisticated robotic surgery.

Operational Excellence and Global Reach

Headquartered in the United States with a worldwide network of facilities, Accuray has established a robust presence in both developed and emerging markets. The company’s strategic partnerships and joint ventures allow it to tailor its products to local market needs, ensuring that precise radiation therapies are available where they are needed most. This global footprint, combined with continuous investment in research and development, makes Accuray a respected name in radiation oncology.

Conclusion

Through its commitment to technical excellence and innovation, Accuray Incorp delivers comprehensive radiotherapy treatment solutions that set the standard of care in radiation oncology. The company’s integrated approach—leveraging advanced technologies to meet complex clinical challenges—has redefined the possibilities in tumor treatment. Investors and industry analysts recognize Accuray not only for its state-of-the-art products but also for its sustainable business model and its pivotal role in enhancing global patient care in radiation therapy.

Stock Performance

$—
0.00%
0.00
Last updated:
-27.52 %
Performance 1 year
$152.2M
Market Cap
102.8M
Shares outstanding

SEC Filings

No SEC filings available for Accuray Incorp.

Financial Highlights

$116,174,000
Revenue (TTM)
$2,537,000
Net Income (TTM)
$0.02
Diluted EPS (TTM)
$1,801,000
Operating Cash Flow
2.18%
Net Profit Margin
4.05%
Oper. Profit Margin

Upcoming Events

April 30, 2025
Q3 FY2025 earnings call

Frequently Asked Questions

What is the current stock price of Accuray Incorp (ARAY)?

The current stock price of Accuray Incorp (ARAY) is $1.58 as of April 25, 2025.

What is the market cap of Accuray Incorp (ARAY)?

The market cap of Accuray Incorp (ARAY) is approximately 152.2M.

What is the revenue (TTM) of Accuray Incorp (ARAY) stock?

The trailing twelve months (TTM) revenue of Accuray Incorp (ARAY) is $116,174,000.

What is the net income of Accuray Incorp (ARAY)?

The trailing twelve months (TTM) net income of Accuray Incorp (ARAY) is $2,537,000.

What is the earnings per share (EPS) of Accuray Incorp (ARAY)?

The diluted earnings per share (EPS) of Accuray Incorp (ARAY) is $0.02 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Accuray Incorp (ARAY)?

The operating cash flow of Accuray Incorp (ARAY) is $1,801,000.

What is the profit margin of Accuray Incorp (ARAY)?

The net profit margin of Accuray Incorp (ARAY) is 2.18%.

What is the operating margin of Accuray Incorp (ARAY)?

The operating profit margin of Accuray Incorp (ARAY) is 4.05%.

What is the gross margin of Accuray Incorp (ARAY)?

The gross profit margin of Accuray Incorp (ARAY) is 36.06%.

What is the current ratio of Accuray Incorp (ARAY)?

The current ratio of Accuray Incorp (ARAY) is 1.62, indicating the company's ability to pay short-term obligations.

What is the gross profit of Accuray Incorp (ARAY)?

The gross profit of Accuray Incorp (ARAY) is $41,892,000 on a trailing twelve months (TTM) basis.

What is the operating income of Accuray Incorp (ARAY)?

The operating income of Accuray Incorp (ARAY) is $4,707,000.

What does Accuray Incorp specialize in?

Accuray focuses on developing, manufacturing, and supporting advanced radiation therapy systems for oncology, including robotic radiosurgery solutions.

What are some key technologies developed by Accuray?

Key technologies include the CyberKnife System, Radixact platforms, ClearRT imaging solutions, Synchrony real-time tracking, and adaptive treatment planning systems.

How do Accuray's systems improve cancer treatment?

Their systems deliver high doses of radiation with sub-millimetre accuracy, continuously tracking patient and tumor movements to ensure precise targeting and reduce treatment side effects.

Who are the primary customers of Accuray?

Primary customers include hospitals, cancer centers, and oncology clinics worldwide that require advanced radiotherapy solutions for effective patient care.

How does Accuray maintain its position in a competitive market?

Accuray invests heavily in R&D, forging strategic partnerships and joint ventures in emerging markets, and continuously innovates its product portfolio to meet evolving clinical needs.

What benefits does real-time tracking technology offer?

Real-time tracking technology automatically adjusts for patient and tumor movement, enhancing treatment precision and allowing clinicians to deliver effective radiation therapy with reduced risk to healthy tissues.

How is Accuray contributing to global cancer care?

By providing advanced, market-changing solutions that simplify complex treatments and expand patient access to precision radiotherapy, Accuray significantly enhances clinical outcomes worldwide.